Loading
France's national genome sequencing programme reports its first results: 239 million euros invested since 2016, and by the end of 2023, 3,109 results returned for cancer patients with a median delivery time of 45 days.
The 2025 French Genomic Medicine Initiative (Plan France Médecine Génomique 2025, PFMG2025) was set up by the French government to bring genome sequencing into routine clinical care nationwide, starting with rare diseases, cancer genetic predisposition and cancers. The paper, written by the programme's contributors, reports that the government had invested 239 million euros since 2016.
By 31 December 2023, 12,737 results had been returned to prescribers for patients with rare diseases or suspected cancer predisposition, with a median delivery time of 202 days and a diagnostic yield of 30.6 per cent, and 3,109 for cancer patients, with a median delivery time of 45 days. The authors name economic sustainability, closer links with research, patient and practitioner empowerment and European collaboration as the programme's next priorities.
The authors describe France as one of the first countries to put genome sequencing into clinical practice nationwide, and for cancer the programme returns results in a median of 45 days, about six weeks. It is a programme report written by the programme, so it describes what was delivered rather than whether sequencing changed what happened to patients.
Shares Hospices Civils de Lyon (HCL), Institut National du Cancer.
Shares Hospices Civils de Lyon (HCL), Institut National du Cancer.
Shares Hospices Civils de Lyon (HCL), Institut National du Cancer.
Shares Hospices Civils de Lyon (HCL), Institut National du Cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/